All In Biotech

Drug Trial Radar · NCT03739710

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

Last checked: Nov 19, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

Jan 24, 2019

Primary completion

May 2, 2024

Study completion May 2, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
iTeos Belgium SA
First posted
Nov 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448/belrestotug.

Conditions

  • Neoplasms

Interventions

  • DocetaxelDrug

    Docetaxel will be administered.

  • FeladilimabDrug

    Feladilimab will be administered.

  • IpilimumabDrug

    Ipilimumab will be administered.

  • GSK4428859ADrug

    GSK4428859A/EOS884448 will be administered.

  • DostarlimabDrug

    Dostarlimab will be administered.

  • GSK6097608Drug

    GSK6097608 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Randomized Across Sub-studiesTime frame: Day 1

Locations

57 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Pinehurst, North Carolina

  • GSK Investigational Site

    Chattanooga, Tennessee

  • GSK Investigational Site

    Nashville, Tennessee

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Edmonton, Alberta, Canada

  • GSK Investigational Site

    Brampton, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Bordeaux, France

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Paris, France

  • GSK Investigational Site

    Saint-Herblain, France

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Berlin, Germany

  • GSK Investigational Site

    Gauting, Germany

  • GSK Investigational Site

    Großhansdorf, Germany

  • GSK Investigational Site

    Heidelberg, Germany

  • GSK Investigational Site

    Immenhausen, Germany

  • GSK Investigational Site

    Kassel, Germany

  • GSK Investigational Site

    Leipzig, Germany

  • GSK Investigational Site

    Meldola FC, Italy

  • GSK Investigational Site

    Milan, Italy

  • GSK Investigational Site

    Naples, Italy

  • GSK Investigational Site

    Orbassano to, Italy

  • GSK Investigational Site

    Ravenna, Italy

  • GSK Investigational Site

    Siena, Italy

  • GSK Investigational Site

    Amsterdam, Netherlands

  • GSK Investigational Site

    Maastricht, Netherlands

  • GSK Investigational Site

    Lodz, Poland

  • GSK Investigational Site

    Poznan, Poland

  • GSK Investigational Site

    Warsaw, Poland

  • GSK Investigational Site

    Bucharest, Romania

  • GSK Investigational Site

    Craiova, Romania

  • GSK Investigational Site

    Floreşti, Romania

  • GSK Investigational Site

    Otopeni, Romania

  • GSK Investigational Site

    Timișoara, Romania

  • GSK Investigational Site

    Chelyabinsk, Russia

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.